Stock listing
NYSE:ANRO Alto Neuroscience, Inc. Stock
Home listing (NYSE) of Alto Neuroscience, Inc.
Follow Alto Neuroscience, Inc. into a list and get an email when it puts out news.
Share price · NYSE:ANRO
$25.37 USD -0.54 (-2.1%)
Close on Nov 20, 2026
- Day range
- $24.40 – $26.48 USDNov 20, 2026
- Volume
- 522,526 sharesNov 20, 2026
- Market cap
- $1.02B USDAt the close on Nov 20, 2026 · price × 40.11M shares outstanding
- 52-week range
- $12.51 – $37.48 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $16.68M USDMedian day 522,526 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NYSE:ANRO · Home | $25.37 USD | -0.54 (-2.1%) | 522,526 | $25.76 | $26.48 | $24.40 | $25.91 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NYSE:ANRO · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $25.37 | -0.54 | -2.1% | $25.76 | $26.48 | $24.40 | 522,526 | |
| $25.91 | +1.00 | +4.0% | $24.99 | $27.75 | $24.95 | 986,150 | |
| $24.91 | -2.21 | -8.1% | $27.10 | $27.12 | $24.79 | 498,655 | |
| $27.12 | -2.42 | -8.2% | $29.13 | $29.54 | $26.95 | 789,240 | |
| $29.54 | -1.08 | -3.5% | $30.01 | $30.76 | $28.54 | 610,910 | |
| $30.62 | -0.53 | -1.7% | $30.44 | $33.46 | $30.35 | 1,288,381 | |
| $31.15 | +2.54 | +8.9% | $29.75 | $31.30 | $28.88 | 1,221,856 | |
| $28.61 | +0.81 | +2.9% | $27.55 | $28.84 | $27.05 | 515,790 | |
| $27.80 | +2.64 | +10.5% | $25.82 | $29.56 | $25.02 | 824,850 | |
| $25.16 | +3.29 | +15.0% | $22.12 | $25.42 | $21.96 | 616,285 | |
| $21.87 | -1.43 | -6.1% | $23.06 | $23.51 | $21.85 | 411,271 | |
| $23.30 | +0.60 | +2.6% | $23.65 | $23.65 | $22.33 | 449,157 | |
| $22.70 | +0.51 | +2.3% | $22.71 | $23.14 | $22.40 | 505,158 | |
| $22.19 | -0.41 | -1.8% | $22.80 | $23.18 | $21.50 | 473,275 | |
| $22.60 | -0.87 | -3.7% | $23.21 | $23.21 | $21.90 | 484,403 | |
| $23.47 | +0.14 | +0.6% | $23.46 | $24.15 | $23.01 | 388,831 | |
| $23.33 | +0.14 | +0.6% | $22.86 | $23.47 | $22.34 | 300,195 | |
| $23.19 | +1.08 | +4.9% | $22.22 | $23.35 | $21.92 | 469,250 | |
| $22.11 | +0.14 | +0.6% | $22.17 | $22.26 | $21.70 | 550,061 | |
| $21.97 | -0.23 | -1.0% | $21.95 | $22.45 | $21.45 | 379,246 | |
| $22.20 | -1.12 | -4.8% | $22.70 | $24.29 | $22.18 | 510,817 | |
| $23.32 | -1.09 | -4.5% | $24.74 | $25.01 | $23.28 | 663,459 | |
| $24.41 | +1.59 | +7.0% | $23.23 | $24.91 | $23.02 | 869,407 | |
| $22.82 | +0.88 | +4.0% | $22.36 | $23.40 | $22.01 | 681,860 | |
| $21.94 | -0.68 | -3.0% | $21.97 | $22.63 | $21.71 | 648,300 | |
| $22.62 | +0.91 | +4.2% | $21.92 | $23.31 | $21.62 | 529,900 | |
| $21.71 | -0.38 | -1.7% | $21.83 | $22.59 | $21.32 | 2,280,100 | |
| $22.09 | -2.06 | -8.5% | $24.04 | $24.20 | $22.07 | 661,800 | |
| $24.15 | -0.22 | -0.9% | $24.34 | $25.25 | $23.86 | 390,300 | |
| $24.37 | +0.34 | +1.4% | $24.00 | $25.11 | $23.81 | 649,400 | |
| $24.03 | +0.51 | +2.2% | $23.03 | $24.05 | $22.81 | 409,800 | |
| $23.52 | -0.17 | -0.7% | $23.39 | $24.42 | $23.33 | 347,900 | |
| $23.69 | -0.32 | -1.3% | $24.06 | $24.70 | $23.50 | 576,300 | |
| $24.01 | -0.79 | -3.2% | $24.63 | $25.85 | $23.80 | 550,300 | |
| $24.80 | -0.51 | -2.0% | $25.64 | $26.10 | $23.87 | 660,700 | |
| $25.31 | -0.22 | -0.9% | $25.50 | $26.49 | $25.12 | 575,800 | |
| $25.53 | -1.05 | -4.0% | $26.87 | $27.41 | $25.53 | 891,600 | |
| $26.58 | -0.08 | -0.3% | $26.44 | $27.42 | $25.75 | 763,400 | |
| $26.66 | +0.17 | +0.6% | $26.36 | $27.76 | $25.89 | 587,000 | |
| $26.49 | -0.69 | -2.5% | $27.36 | $27.62 | $26.48 | 366,300 | |
| $27.18 | -0.32 | -1.2% | $27.51 | $27.91 | $26.39 | 788,400 | |
| $27.50 | -3.28 | -10.7% | $30.39 | $30.62 | $26.41 | 639,900 | |
| $30.78 | +0.15 | +0.5% | $30.71 | $31.46 | $30.18 | 347,100 | |
| $30.63 | +0.36 | +1.2% | $30.64 | $30.81 | $29.80 | 357,800 | |
| $30.27 | -0.71 | -2.3% | $31.32 | $31.65 | $30.08 | 2,199,200 | |
| $30.98 | +0.98 | +3.3% | $30.59 | $31.65 | $30.11 | 411,000 | |
| $30.00 | -0.25 | -0.8% | $30.50 | $31.21 | $29.87 | 548,400 | |
| $30.25 | -1.43 | -4.5% | $31.40 | $31.40 | $29.95 | 420,400 | |
| $31.68 | -0.32 | -1.0% | $31.96 | $32.99 | $31.16 | 453,300 | |
| $32.00 | +0.32 | +1.0% | $32.00 | $33.13 | $31.11 | 415,700 | |
| $31.68 | -2.39 | -7.0% | $33.71 | $34.20 | $31.35 | 790,000 | |
| $34.07 | -1.74 | -4.9% | $35.48 | $36.91 | $33.91 | 556,800 | |
| $35.81 | +0.26 | +0.7% | $34.69 | $36.84 | $34.08 | 580,900 | |
| $35.55 | -0.85 | -2.3% | $36.18 | $36.98 | $35.45 | 269,900 | |
| $36.40 | -0.24 | -0.7% | $36.84 | $37.36 | $35.91 | 324,700 | |
| $36.64 | +1.44 | +4.1% | $35.97 | $37.39 | $35.22 | 432,800 | |
| $35.20 | -0.18 | -0.5% | $35.20 | $36.04 | $34.62 | 350,100 | |
| $35.38 | +0.25 | +0.7% | $34.89 | $35.83 | $33.98 | 764,100 | |
| $35.13 | -1.17 | -3.2% | $35.00 | $35.72 | $34.73 | 246,700 | |
| $36.30 | -0.23 | -0.6% | $36.08 | $36.82 | $35.46 | 359,600 | |
| $36.53 | +0.22 | +0.6% | $35.80 | $36.86 | $34.87 | 282,800 | |
| $36.31 | +0.06 | +0.2% | $36.52 | $37.48 | $35.74 | 474,000 | |
| $36.25 | +1.97 | +5.7% | $33.96 | $36.99 | $33.52 | 867,900 | |
| $34.28 | +0.03 | +0.1% | $34.44 | $35.29 | $33.66 | 291,100 | |
| $34.25 | -0.64 | -1.8% | $34.36 | $34.65 | $33.65 | 313,900 |
- Ticker
- NYSE:ANRO
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NYSE
- Currency
- USD
What changed lately
Latest news release · Nov 10, 2026
Alto Neuroscience Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Latest deck · January 2026
Investor Presentation (January 2026)
Investor deck · 70 slides
Latest news
Alto Neuroscience Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Nov 10, 2026
Closed $31.15 (+8.9%) on Nov 11, 2026
Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08
Nov 4, 2026
Closed $23.30 (+2.6%) on Nov 4, 2026
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
Nov 3, 2026
Closed $22.70 (+2.3%) on Nov 3, 2026
Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer
Aug 27, 2026
Closed $35.13 (-3.2%) on Aug 28, 2026
Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Aug 12, 2026
Closed $32.30 (+10.7%) on Aug 13, 2026
Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock
Jul 13, 2026
Closed $28.03 (+5.9%) on Jul 13, 2026
Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia
Jun 15, 2026
Closed $21.17 (-1.4%) on Jun 15, 2026
Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors
May 28, 2026
Closed $20.22 (-1.1%) on May 28, 2026
Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award
May 15, 2026
Closed $22.98 (-2.6%) on May 15, 2026
Alto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlights
May 13, 2026
Closed $22.85 (-7.2%) on May 13, 2026
Alto Neuroscience, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 24 in the last 12 months · 41 in all · newest Nov 10, 2026 · oldest 2025
- Decks
- 3 decks · latest January 2026
Where Alto Neuroscience, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NYSE:ANRO · Home listing · This page | NYSE | United States | USD |
| BOATS:ANRO | BOATS | United States | USD |
Valuation
Price/book 3.4× against a median of 4.7×: 4th lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $711.7M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 3.4×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.1×
- Beta vs S&P 500
- 1.65
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Alto Neuroscience, Inc. · NYSE:ANRO | US$1.02B | US$711.7M | n/a | n/a | n/a | 3.4× | n/a | 0.1× | 1.65 |
| MedinCell SA · EURONEXT:MEDCL | US$1.05B | US$1.02B | n/a | 38.4× | n/a | 313× | −128.9% | 18.7× | n/a |
| Nektar Therapeutics · NASDAQ:NKTR | US$1.03B | US$492.8M | n/a | 9.4× | n/a | 1.2× | −339.7% | 0.1× | 1.28 |
| Mabwell (Shanghai) Bioscience Co., Ltd. Class A · SSE:688062 | US$1.02B | US$984.8M | n/a | 9.2× | n/a | 9.5× | −146.4% | 2.9× | n/a |
| SpyGlass Pharma, Inc. · NASDAQ:SGP | US$1.02B | US$809.5M | n/a | n/a | n/a | 4.8× | n/a | 0.0× | 1.01 |
| Inhibrx Biosciences, Inc. · NASDAQ:INBX | US$1.02B | US$1.09B | n/a | 546× | n/a | n/a | n/a | n/a | 1.89 |
| Duality Biotherapeutics, Inc. · HKEX:9606 | US$992.3M | US$609.0M | n/a | 4.8× | n/a | 4.6× | −170.8% | 0.3× | n/a |
| Peptron, Inc. · KRX:087010 | US$985.3M | US$948.0M | n/a | 211× | n/a | 10.2× | −342.2% | 0.2× | n/a |
| Omeros Corporation · NASDAQ:OMER | US$983.7M | US$920.3M | 10.0× | 12.4× | n/a | n/a | 132.3% | n/a | 1.64 |
| Everest Medicines Ltd. · HKEX:1952 | US$981.5M | US$1.00B | n/a | 2.8× | 183× | 1.3× | −2.2% | 0.4× | n/a |
| HBM Holdings Ltd. · HKEX:2142 | US$981.4M | US$711.5M | 10.7× | 4.5× | 8.6× | 2.4× | 57.8% | 0.2× | n/a |
| Median of the others | US$1.00B | US$934.1M | 10.4× | 9.4× | 95.9× | 4.7× | −137.6% | 0.2× | 1.46 |
Forecasts
10 strong buy · 1 hold · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 38.67 USD · Analysts' mean
- EPS, year to Dec 2026
- -2.48 · 2 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Amit Etkin | Founder, President, and Chief Executive Officer |
| Nick Smith | President and Chief Financial Officer |
| Michael Hanley | Chief Operating Officer |
| Erin R. McQuade | General Counsel and Chief Administrative Officer |
| Adam Savitz | Chief Medical Officer |
| Jessica Powell | Chief Development Officer |
Board
| Director | Role |
|---|---|
| Amit Etkin | Founder, President, and Chief Executive Officer |
| Andrew Dreyfus | Board Member |
| Andrew Miller | Board Member |
| Christopher Nixon Cox | Board Member |
| Gwill York | Board Member |
| Husseini Manji | Board Member |
| Raymond Sanchez | Board Member |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 10, 2026 · After close | +8.9% |
| Q2 2026 | Aug 12, 2026 · After close | +10.7% |
| Q1 2026 | May 13, 2026 · Before open | −7.2% |
| Q4 2025 | Mar 20, 2026 | −9.2% |
| Q3 2025 | Nov 12, 2025 · Before open | +6.0% |
| Q2 2025 | Aug 13, 2025 · After close | −0.3% |
| Q1 2025 | May 14, 2025 · After close | +10.4% |
| Q4 2024 | Mar 20, 2025 | −5.4% |
| Q3 2024 | Nov 12, 2024 · After close | +0.7% |
| Q2 2024 | Aug 13, 2024 · After close | +6.0% |
All 12 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 14, 2024 · After close | −2.3% |
| Q4 2023 | Mar 21, 2024 · After close | +5.4% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (January 2026) | Investor deck | 70 slides | January 2026 |
| TD Cowen 45th Annual Health Care Conference (March 2025) | Conference | 17 slides | Mar 4, 2025 |
| Investor Day (September 2024) | Investor day | 74 slides | Sep 9, 2024 |
Financings
| Raise | Date |
|---|---|
| Registered direct offering of common stock Announced: about US$100M · US$26.48 a share · BofA Securities +4 Dealers: BofA Securities (co-lead), Stifel (co-lead), William Blair (co-lead), Baird (co-lead), Jones Buyers: EcoR1 Capital Use of proceeds: Accelerate and expand clinical development of ALTO-207, including an additional Phase 3 trial in treatment-resistant depression, and working capital | Jul 13, 2026 |
| Private placement of private placement financing (PIPE) Closed: US$50M raised · US$5.914 a share Buyers: Perceptive Advisors (Led the financing); Commodore Capital; Vestal Point Capital; Vivo Capital Use of proceeds: To support the accelerated development of ALTO-207 following the successful FDA meeting | Nov 12, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$16.00 a share on Feb 1, 2024.
- Price
- US$16.00 a share
- Shares offered
- 8,040,000 shares of common stock
- Offering size
- US$128.6 million
- Underwriters' option
- Up to 1,206,000 more shares
- Underwriters
- Jefferies, TD Cowen, Stifel, William Blair, Baird · In the order on the cover
- Shares delivered
- On or about Feb 6, 2024
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Nov 22, 2023 |
| Filed publicly | Jan 12, 2024 |
| Amended twice | Newest Jan 29, 2024 |
| Shares registered with an exchange | Jan 30, 2024 |
| Declared effective by the SEC | Feb 1, 2024 |
| Final prospectus, with the price | Feb 5, 2024 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Feb 5, 2024 |
| EFFECT · Notice that a registration is effective | Feb 1, 2024 |
| S-1MEF · Registration of more shares for the same offering | Feb 1, 2024 |
| CERT · Exchange's certificate of listing | Jan 30, 2024 |
| 8-A12B · Registration of shares for listing on an exchange | Jan 30, 2024 |
| CORRESP · Letter to the SEC | Jan 30, 2024 |
| CORRESP · Letter to the SEC | Jan 30, 2024 |
| S-1/A · Registration statement, amended | Jan 29, 2024 |
| S-1/A · Registration statement, amended | Jan 29, 2024 |
| CORRESP · Letter to the SEC | Jan 25, 2024 |
All 20 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Jan 24, 2024 |
| UPLOAD · Letter from the SEC | Jan 23, 2024 |
| CORRESP · Letter to the SEC | Jan 19, 2024 |
| CORRESP · Letter to the SEC | Jan 12, 2024 |
| S-1 · Registration statement | Jan 12, 2024 |
| UPLOAD · Letter from the SEC | Jan 9, 2024 |
| DRSLTR · Letter to the SEC with a draft | Dec 28, 2023 |
| DRS/A · Draft registration statement, amended | Dec 28, 2023 |
| UPLOAD · Letter from the SEC | Dec 19, 2023 |
| DRS · Draft registration statement | Nov 22, 2023 |
Open IPO · From the cover of the final prospectus (424B4) filed Feb 5, 2024
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2025 | FY2024 | FY2024 | FY2023 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 210.0K | |||
| Cost of revenue | 661.0K | 502.0K | 373.0K | 342.0K | 145.0K | |||
| Gross profit | -661.0K | -502.0K | -373.0K | -342.0K | 65.0K | |||
| Research and development | 45.6M | 45.6M | 47.0M | 47.0M | 30.3M | 30.3M | 23.7M | 8.37M |
| Selling, general and administrative | 20.7M | 21.6M | 7.52M | 5.50M | 3.90M | |||
| Operating income | -66.4M | -66.4M | -68.6M | -68.6M | -37.8M | -37.8M | -29.2M | -12.1M |
| Depreciation and amortization | 661.0K | 661.0K | 502.0K | 502.0K | 373.0K | 373.0K | 342.0K | 145.0K |
| EBITDA | -65.7M | -65.7M | -68.1M | -68.1M | -37.4M | -37.4M | -28.9M | -11.9M |
| Interest expense | 2.47M | 2.47M | 1.38M | 1.38M | 1.37M | 1.37M | 0 | |
| Income before tax | -63.2M | -61.4M | -36.3M | -27.7M | -9.19M | |||
| Income tax | 0 | 0 | -61.4M | 0 | ||||
| Net income | -63.2M | -63.2M | -61.4M | -61.4M | -36.3M | -36.3M | -27.7M | -9.19M |
| Earnings per share, basic | -2.19 | -2.19 | -2.50 | -2.50 | -9.73 | -1.35 | -1.08 | -0.36 |
| Earnings per share, diluted | -2.19 | -2.50 | -9.73 |
Balance sheet
| Line | FY2025 | FY2025 | FY2024 | FY2024 | FY2023 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 176.5M | 176.5M | 168.2M | 168.2M | 82.5M | 82.5M | 48.3M | 25.7M |
| Receivables | 8.00K | 546.0K | 1.74M | |||||
| Inventory | 0 | |||||||
| Current assets | 177.7M | 177.7M | 169.3M | 169.3M | 85.4M | 85.4M | 49.2M | 27.7M |
| Property, plant and equipment | 1.87M | 2.67M | 1.11M | |||||
| Total assets | 184.7M | 184.7M | 177.5M | 177.5M | 86.6M | 86.6M | 50.9M | 28.8M |
| Accounts payable | 1.88M | 1.88M | 1.58M | 1.58M | 1.07M | 1.07M | 1.61M | 600.0K |
| Current liabilities | 11.3M | 11.3M | 10.0M | 10.0M | 5.61M | 5.61M | 5.56M | 1.81M |
| Long-term debt | 16.2M | 18.4M | 10.3M | 11.6M | 9.86M | 9.86M | 9.46M | |
| Total debt | 16.8M | 4.41M | 10.3M | 16.9M | 9.86M | 9.99M | 82.1M | 38.2M |
| Total liabilities | 33.5M | 33.5M | 26.1M | 26.1M | 16.8M | 158.3M | 89.3M | 41.3M |
| Shareholders' equity | 151.1M | 151.1M | 151.5M | 151.5M | -71.7M | -71.7M | -38.4M | -12.5M |
| Shares outstanding | 31.9M | 28.9M | 27.0M | 24.6M | 3.83M | 26.9M | 25.6M | 25.6M |
Cash flow
| Line | FY2025 | FY2025 | FY2024 | FY2024 | FY2023 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -51.8M | -51.8M | -47.4M | -47.4M | -33.4M | -33.4M | -20.4M | -9.26M |
| Capital spending | -24.0K | -24.0K | -2.08M | -2.08M | -470.0K | -470.0K | -732.0K | -680.0K |
| Free cash flow | -51.8M | -51.8M | -49.5M | -49.5M | -33.9M | -33.9M | -21.1M | -9.94M |
| Cash from investing | -24.0K | -24.0K | -2.08M | -2.08M | -470.0K | -470.0K | -732.0K | -680.0K |
| Cash from financing | 60.1M | 60.1M | 135.7M | 135.7M | 68.1M | 68.1M | 43.8M | 31.7M |
| Share buybacks | -167.0K | 0 | ||||||
| Change in cash | 8.26M | 8.26M | 86.2M | 86.2M | 34.2M | 34.2M | 22.6M | 21.7M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 16, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 10, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 10, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 30, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 1, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 29, 2026 | Other filings | SEC |
| 8-K · Current report | Aug 27, 2026 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
All 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 27, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 20, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jul 14, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Jul 14, 2026 | Offer document | SEC |
| 8-K · Current report | Jul 13, 2026 | Results | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 29, 2026 | Insider trade | SEC |
| 8-K · Current report | May 28, 2026 | Management or board change | SEC |
| 4 · Change in ownership | May 15, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
| 8-K · Current report | May 13, 2026 | Management or board change | SEC |
| 10-Q · Quarterly report | May 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2026 | Results | SEC |
| EFFECT · Notice that a registration is effective | Apr 21, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 17, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 16, 2026 | Other filings | SEC |
| S-3 · Registration statement | Apr 10, 2026 | Offer document | SEC |
| 8-K · Current report | Apr 1, 2026 | Current report | SEC |
| ARS · Annual report to shareholders | Mar 26, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Mar 26, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Mar 26, 2026 | Meeting notice | SEC |
| 8-K · Current report | Mar 16, 2026 | Material contract | SEC |
| S-8 · Registration statement for employee plans | Mar 16, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 16, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 16, 2026 | Results | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 18, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Dec 11, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 8, 2025 | Other filings | SEC |
| S-3 · Registration statement | Nov 26, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2025 | Results | SEC |
| D | Oct 27, 2025 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 27, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Oct 20, 2025 | Material contract | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 10, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 14, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 14, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 16, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 8, 2025 | Insider trade | SEC |
| 8-K · Current report | Jul 8, 2025 | Management or board change | SEC |
| 8-K · Current report | Jun 26, 2025 | Current report | SEC |
| 8-K · Current report | Jun 3, 2025 | Material contract | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | May 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 15, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2025 | Results | SEC |
| DEFR14A | May 9, 2025 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Apr 1, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 1, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 1, 2025 | Meeting notice | SEC |
| S-8 · Registration statement for employee plans | Mar 20, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 20, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 20, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Feb 12, 2025 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Feb 12, 2025 | Other filings | SEC |
| 4 · Change in ownership | Feb 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 7, 2025 | Insider trade | SEC |
| CORRESP · Letter to the SEC | Feb 7, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Feb 7, 2025 | Other filings | SEC |
| 8-K · Current report | Feb 3, 2025 | Results | SEC |
| S-3 · Registration statement | Feb 3, 2025 | Offer document | SEC |
| 8-K · Current report | Jan 16, 2025 | Material contract | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2024 | Results | SEC |
| SC 13G · Big-stake notice | Nov 12, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 8, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Oct 22, 2024 | Current report | SEC |
| SC 13G · Big-stake notice | Oct 21, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2024 | Results | SEC |
| 8-K · Current report | Jul 29, 2024 | Material contract | SEC |
| 4 · Change in ownership | Jul 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 22, 2024 | Insider trade | SEC |
| 8-K · Current report | May 21, 2024 | Management or board change | SEC |
| 10-Q · Quarterly report | May 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2024 | Results | SEC |
| 4 · Change in ownership | Apr 1, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Mar 29, 2024 | Big-stake notice | SEC |
| 10-K · Annual report | Mar 21, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 21, 2024 | Results | SEC |
| 4 · Change in ownership | Mar 12, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 12, 2024 | Insider trade | SEC |
| 8-K · Current report | Mar 11, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Mar 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Feb 9, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 7, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Feb 7, 2024 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Feb 6, 2024 | Offer document | SEC |
| 8-K · Current report | Feb 6, 2024 | Current report | SEC |
| 4 · Change in ownership | Feb 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 5, 2024 | Insider trade | SEC |
| 424B4 · Prospectus | Feb 5, 2024 | Offer document | SEC |
| 3 · Initial statement of ownership | Feb 2, 2024 | Insider trade | SEC |
| SEC STAFF LETTER | Feb 2, 2024 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Feb 2, 2024 | Other filings | SEC |
| 3 · Initial statement of ownership | Feb 1, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 1, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 1, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 1, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 1, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 1, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 1, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 1, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 1, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 1, 2024 | Insider trade | SEC |
| S-1MEF · Registration of more shares for the same offering | Feb 1, 2024 | Offer document | SEC |
| CERT · Exchange's certificate of listing | Jan 30, 2024 | Other filings | SEC |
| 8-A12B · Registration of shares for listing on an exchange | Jan 30, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 30, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 30, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | Jan 29, 2024 | Offer document | SEC |
| S-1/A · Registration statement, amended | Jan 29, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jan 25, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 24, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jan 23, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 19, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 12, 2024 | Other filings | SEC |
| S-1 · Registration statement | Jan 12, 2024 | Offer document | SEC |
| SEC STAFF LETTER | Jan 10, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jan 9, 2024 | Other filings | SEC |
| DRSLTR · Letter to the SEC with a draft | Dec 28, 2023 | Other filings | SEC |
| DRS/A · Draft registration statement, amended | Dec 28, 2023 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Dec 19, 2023 | Other filings | SEC |
| D | Nov 27, 2023 | Other filings | SEC |
| D | Nov 27, 2023 | Other filings | SEC |
| D | Nov 27, 2023 | Other filings | SEC |
| D | Nov 27, 2023 | Other filings | SEC |
| DRS · Draft registration statement | Nov 22, 2023 | Offer document | SEC |
Cap table
Built by 6ix from Alto Neuroscience, Inc.’s releases · as of Nov 5, 2026
- Common shares
- 40,110,620
- Fully diluted
- 40,110,620
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 40,110,620 | Nov 5, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 5, 2026 | 40,110,620 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Christopher Nixon Cox Other companies: High-Trend International Group (Director · Since at least Mar 7, 2026); Newsmax, Inc. (Director · Since at least Mar 28, 2025) | Board Member · Since at least Feb 1, 2024 |
| Maha Radhakrishnan Other companies: Candel Therapeutics, Inc. (Director · Since at least Jun 4, 2025); Entrada Therapeutics, Inc. (Industry Leader and Independent Director · Since at least Jun 1, 2025) | Director · Mar 8, 2024 – Mar 8, 2024 · Past |
| Ramiro Sanchez Other companies: Rapport Therapeutics, Inc. (Director · Since at least Nov 7, 2024); Cerevel Therapeutics Holdings Inc (Chief Medical Officer · Oct 27, 2020 – Aug 1, 2024 · Past) | Director · Since at least Aug 12, 2025 |
| Adam Savitz | Chief Medical Officer · Since at least Jun 26, 2025 |
| Amit Etkin | Founder, President, and Chief Executive Officer · Since at least Feb 1, 2024 |
| Andrew Dreyfus | Board Member · Since at least Nov 5, 2026 |
| Andrew Miller | Board Member · Since at least May 28, 2026 |
| Erin R. McQuade | General Counsel and Chief Administrative Officer · Since at least Nov 5, 2026 |
| Gwill York | Director · Since at least Feb 1, 2024 |
| Husseini Manji | Board Member · Since at least May 15, 2026 |
All 17 people
| Person | Seat |
|---|---|
| Jessica Powell | Chief Development Officer · Since at least Nov 5, 2026 |
| Michael Conick Hanley Jr | CHIEF OPERATING OFFICER · Since at least May 20, 2024 |
| Michael Hanley | Chief Operating Officer · Since at least Nov 5, 2026 |
| Nicholas Conrad Smith | PRESIDENT AND CFO · Since at least Jul 3, 2025 |
| Nick Smith | President and Chief Financial Officer · Since at least Aug 27, 2026 |
| Po Yu Chen | Director · Feb 1, 2024 – Feb 6, 2024 · Past |
| Raymond Sanchez | Board Member · Since at least Aug 13, 2025 |
Log in to ask 6ix AI your own questions about Alto Neuroscience, Inc.